Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medivir ABOSTO:MVIR -1.10%50 Return-on-Tangible-Equity is -35.27% as of Mar. 2026. GuruFocus rates OSTO:MVIR with a GF Score™ of 50/100 and a GF Value™ of kr1.11 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Medivir AB ranks worse than 89.99% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medivir AB's annualized net income for the quarter that ended in Mar. 2026 was kr-37.60 Mil. Medivir AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr106.61 Mil. Therefore, Medivir AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -35.27%.
The historical rank and industry rank for Medivir AB's Return-on-Tangible-Equity or its related term are showing as below:
OSTO:MVIR'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -263.34 Med: -72.83 Max: 21.16
Current: -263.34
During the past 13 years, Medivir AB's highest Return-on-Tangible-Equity was 21.16%. The lowest was -263.34%. And the median was -72.83%.
OSTO:MVIR's Return-on-Tangible-Equity is ranked worse than 89.99% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs OSTO:MVIR: -263.34
Medivir AB (OSTO:MVIR) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medivir AB Return-on-Tangible-Equity Related Terms
Medivir AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medivir AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MVIR vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Medivir AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medivir AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -35.27% mean?
Medivir AB (OSTO:MVIR) has a Return-on-Tangible-Equity of -35.27% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medivir AB and its competitors. According to the industry distribution chart, Medivir AB ranks #1079 out of 1199 companies in the Biotechnology industry, placing it in the top 90%.
Is Medivir AB's Return-on-Tangible-Equity too high?
Medivir AB's current Return-on-Tangible-Equity is -35.27%. Based on the distribution chart, Medivir AB ranks #1079 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medivir AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #1079 out of 1199 companies for Return-on-Tangible-Equity. This places Medivir AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medivir AB and its competitors. Medivir AB's current Return-on-Tangible-Equity is -35.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.80 — trading 62.2% above its estimated fair value. The current Return-on-Tangible-Equity is -35.27%. Medivir AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current Return-on-Tangible-Equity is -35.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (OSTO:MVIR) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.80 is trading 62.2% above its estimated GF Value™ of kr1.11.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for OSTO:MVIR:
Return-on-Tangible-Equity: -35.27%
GF Value™: kr1.11 vs. price of kr1.80 (62.2% above fair value)
No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score
Get the complete analysis for OSTO:MVIR
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MVIR has been successfully added to your 
